Compare WDFC & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WDFC | TLX |
|---|---|---|
| Founded | 1953 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | WDFC | TLX |
|---|---|---|
| Price | $240.59 | $6.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $300.00 | $21.00 |
| AVG Volume (30 Days) | 168.0K | ★ 178.9K |
| Earning Date | 01-08-2026 | 01-19-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ 26.07 | N/A |
| EPS | ★ 6.58 | 0.04 |
| Revenue | $620,913,000.00 | ★ $664,225,558.00 |
| Revenue This Year | $7.14 | N/A |
| Revenue Next Year | $6.02 | N/A |
| P/E Ratio | ★ $36.41 | $150.68 |
| Revenue Growth | 2.86 | ★ 55.35 |
| 52 Week Low | $175.38 | $6.40 |
| 52 Week High | $253.48 | $30.36 |
| Indicator | WDFC | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 65.83 | 32.32 |
| Support Level | $234.19 | $6.94 |
| Resistance Level | $253.24 | $7.43 |
| Average True Range (ATR) | 7.04 | 0.25 |
| MACD | 0.51 | -0.05 |
| Stochastic Oscillator | 65.98 | 1.46 |
WD-40 Co is a global marketing organization focused on developing and selling products that solve maintenance and cleaning problems internationally. It offers two product groups: maintenance products, including the flagship WD-40 Multi-Use Product, which serves as a lubricant, rust preventative, penetrant, and moisture displacer, marketed globally; and homecare and cleaning products, mainly sold in North America, the UK, and Australia. The company distributes its products through hardware stores, automotive parts outlets, industrial suppliers, mass retailers, online platforms, and specialty retailers across the Americas, EIMEA, and Asia-Pacific, with the majority of revenue generated in the Americas.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.